Nothing Special   »   [go: up one dir, main page]

HK1048266A1 - Pharmaceutically stable oxaliplatinum preparation for parenteral administration. - Google Patents

Pharmaceutically stable oxaliplatinum preparation for parenteral administration.

Info

Publication number
HK1048266A1
HK1048266A1 HK03100569A HK03100569A HK1048266A1 HK 1048266 A1 HK1048266 A1 HK 1048266A1 HK 03100569 A HK03100569 A HK 03100569A HK 03100569 A HK03100569 A HK 03100569A HK 1048266 A1 HK1048266 A1 HK 1048266A1
Authority
HK
Hong Kong
Prior art keywords
parenteral administration
preparation
pharmaceutically stable
solution
oxaliplatinum
Prior art date
Application number
HK03100569A
Other versions
HK1048266B (en
Inventor
Houssam Ibrahim
Martine Bayssas
Henri Pourrat
Christine Deuschel
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of HK1048266A1 publication Critical patent/HK1048266A1/en
Publication of HK1048266B publication Critical patent/HK1048266B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

The invention concerns a pharmaceutically stable oxaliplatinum preparation for parenteral administration, the oxaliplatinum being in a precipitate-free, colourless and clear solution after being preserved for a pharmaceutically acceptable duration. In said preparation, the oxiplatinum is contained in solution in a solvent at a concentration of at least 7 mg/ml and the solvent comprises a sufficient amount of at least a hydroxylated derivative selected among 1,2-propane-diol, glycerol, maltitol, saccharose and inositol. The invention also concerns a method for preparing said solution.
HK03100569.8A 1999-08-30 2003-01-23 Pharmaceutically stable oxaliplatinum preparation for parenteral administration HK1048266B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15135799P 1999-08-30 1999-08-30
PCT/CH2000/000462 WO2001015691A1 (en) 1999-08-30 2000-08-30 Pharmaceutically stable oxaliplatinum preparation for parenteral administration

Publications (2)

Publication Number Publication Date
HK1048266A1 true HK1048266A1 (en) 2003-03-28
HK1048266B HK1048266B (en) 2005-04-01

Family

ID=22538394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100569.8A HK1048266B (en) 1999-08-30 2003-01-23 Pharmaceutically stable oxaliplatinum preparation for parenteral administration

Country Status (19)

Country Link
EP (1) EP1207875B1 (en)
JP (1) JP4890711B2 (en)
KR (1) KR100688217B1 (en)
CN (1) CN1170533C (en)
AT (1) ATE249825T1 (en)
AU (1) AU768169B2 (en)
BR (1) BRPI0013613B8 (en)
CA (1) CA2382389C (en)
CZ (1) CZ298581B6 (en)
DE (1) DE60005376T2 (en)
DK (1) DK1207875T3 (en)
ES (1) ES2206288T3 (en)
HK (1) HK1048266B (en)
MX (1) MXPA02002266A (en)
PT (1) PT1207875E (en)
RU (1) RU2252022C2 (en)
UA (1) UA71985C2 (en)
WO (1) WO2001015691A1 (en)
ZA (1) ZA200200800B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223013A1 (en) * 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
TWI236486B (en) * 2001-10-10 2005-07-21 Mitsui Chemicals Inc Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DE10314377A1 (en) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid
JP2007504098A (en) * 2003-08-28 2007-03-01 メイン・ファーマ・リミテッド Oxaliplatin formulation containing acid
CZ300795B6 (en) * 2003-09-02 2009-08-12 Pliva-Lachema A. S. Pharmaceutical composition and process for its preparation
WO2005051966A1 (en) 2003-11-25 2005-06-09 Platco Technologies (Proprietary) Limited Platinum(ii) complexes, preparation and use
ATE431828T1 (en) 2004-09-01 2009-06-15 Platco Technologies Proprietar PRODUCTION OF PLATINUM(II) COMPLEXES
DE102004052877B4 (en) 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stable aqueous formulations of a platinum derivative
CN1311818C (en) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 Pharmaceutical composition for solid tumour
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
MX2008009774A (en) 2006-01-30 2008-10-17 Platco Technologies Proprietar Preparation of platinum (ll) complexes.
CZ300665B6 (en) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterile liquid pharmaceutical composition and process for preparing thereof
CZ300664B6 (en) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterile liquid pharmaceutical composition and process for preparing thereof
KR200449655Y1 (en) * 2009-11-20 2010-07-28 김명환 Portable umbrella sealed with case having auxillary haadle cap
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011227083B2 (en) 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
CN102670526B (en) * 2012-05-10 2013-12-04 南京臣功制药股份有限公司 Oxaliplatin freeze-dried powder injection and preparation method thereof
JP5314790B1 (en) * 2012-07-09 2013-10-16 東和薬品株式会社 Oxaliplatin-containing pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
ATE338553T1 (en) * 1997-03-07 2006-09-15 Sanofi Aventis Us Llc ANTITUMOR COMBINATION OF 3-AMINO-1,2,4-BENZOTRIAZINE 1,4-DIOXIDE/PACLITAXEL/PLATINUM
JP3774043B2 (en) * 1997-09-12 2006-05-10 彰 辻 Malignant tumor diagnostic agent
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations

Also Published As

Publication number Publication date
RU2252022C2 (en) 2005-05-20
ZA200200800B (en) 2003-06-25
JP4890711B2 (en) 2012-03-07
ATE249825T1 (en) 2003-10-15
EP1207875A1 (en) 2002-05-29
BRPI0013613B8 (en) 2021-05-25
CA2382389A1 (en) 2001-03-08
CA2382389C (en) 2010-06-29
PT1207875E (en) 2004-02-27
BR0013613A (en) 2002-05-14
EP1207875B1 (en) 2003-09-17
CN1371278A (en) 2002-09-25
JP2003508436A (en) 2003-03-04
KR100688217B1 (en) 2007-02-28
DE60005376D1 (en) 2003-10-23
HK1048266B (en) 2005-04-01
AU768169B2 (en) 2003-12-04
DE60005376T2 (en) 2004-07-01
AU6553000A (en) 2001-03-26
BR0013613B1 (en) 2013-05-28
CZ298581B6 (en) 2007-11-14
DK1207875T3 (en) 2004-01-19
WO2001015691A1 (en) 2001-03-08
CN1170533C (en) 2004-10-13
MXPA02002266A (en) 2003-08-20
UA71985C2 (en) 2005-01-17
ES2206288T3 (en) 2004-05-16
KR20020033782A (en) 2002-05-07
CZ2002291A3 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
HK1048266A1 (en) Pharmaceutically stable oxaliplatinum preparation for parenteral administration.
Catimel et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors
EP0261429B1 (en) Penetration enhancement systems and the preparation thereof
CA2269947A1 (en) Covalent polar lipid conjugates for targeting
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
WO2000007979A3 (en) Compounds and compositions for delivering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
GR3035536T3 (en) Liquid compositions containing cyclosporin and process for their preparation.
BG104560A (en) Long active injectable formulations containing hydrogenated castor oil
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
NZ312715A (en) Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
WO2002015903A3 (en) Novel pharmaceutical composition for administering n-0923
IL149337A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
EP1022026A3 (en) Pharmaceutical compositions for treating nitrate-induced tolerance
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
EP0959874A4 (en)
EP0228253A1 (en) Rectally absorbable form of L-dopa
KR100738940B1 (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
KR970706792A (en) The lyophilizate of lipid complex of water insoluble camptothecins of water-insoluble camptothecin.
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU1704801A (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
CA2393344A1 (en) Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6825177B2 (en) Aryl phosphate derivatives of d4T with potent anti-viral activity
GB9420748D0 (en) 1,5 benzodiazepine derivatives
TOKUNAGA et al. Liposomal Sustained-Release Delivery Systems for Intravenous Injection. V. Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-Darabinofuranosylcytosine

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20200829